clinical trials semaglutide Long-term weight loss effects of in obesity without diabetes in the SELECT trial Clinical Trials Overview Semaglutide Molecule

Safety: In September 2025, the FDA issued a statement that compounded semaglutide is risky because these products do not undergo the FDAs review for safety, effectiveness, and quality before being offered to patients

Most commonly reported side effects

Certain risk factors can make you more prone to developing a B12 deficiency

Reconstituted DSIP should be refrigerated at 2-8C and used within 4 weeks

it can only be accessed through a regulated clinical trial

Whilst these medications have demonstrated significant efficacy in glycaemic control and weight reduction, their potential role in addressing disordered eating patterns, including binge eating, has emerged as an area of clinical and research interest